CMPX vs. PCB, MGX, AGEN, IPSC, ADVM, IPHA, KOD, CHRS, FENC, and INMB
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include PCB Bancorp (PCB), Metagenomi (MGX), Agenus (AGEN), Century Therapeutics (IPSC), Adverum Biotechnologies (ADVM), Innate Pharma (IPHA), Kodiak Sciences (KOD), Coherus BioSciences (CHRS), Fennec Pharmaceuticals (FENC), and INmune Bio (INMB).
PCB Bancorp (NASDAQ:PCB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
PCB Bancorp has a net margin of 14.69% compared to PCB Bancorp's net margin of 0.00%. Compass Therapeutics' return on equity of 9.09% beat PCB Bancorp's return on equity.
In the previous week, Compass Therapeutics had 16 more articles in the media than PCB Bancorp. MarketBeat recorded 20 mentions for Compass Therapeutics and 4 mentions for PCB Bancorp. PCB Bancorp's average media sentiment score of 0.87 beat Compass Therapeutics' score of 0.42 indicating that Compass Therapeutics is being referred to more favorably in the news media.
33.0% of PCB Bancorp shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 25.0% of PCB Bancorp shares are owned by company insiders. Comparatively, 30.0% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
PCB Bancorp presently has a consensus price target of $17.00, indicating a potential upside of 9.68%. Compass Therapeutics has a consensus price target of $9.00, indicating a potential upside of 456.72%. Given PCB Bancorp's stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than PCB Bancorp.
Compass Therapeutics received 12 more outperform votes than PCB Bancorp when rated by MarketBeat users. Likewise, 72.73% of users gave Compass Therapeutics an outperform vote while only 48.00% of users gave PCB Bancorp an outperform vote.
PCB Bancorp has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
PCB Bancorp has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than PCB Bancorp, indicating that it is currently the more affordable of the two stocks.
Summary
Compass Therapeutics beats PCB Bancorp on 10 of the 17 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
